good health pharma & supplies inc.

2830 frederick douglas blvd.
new york, new york 10039

NYS Entity Status
ACTIVE

NYS Filing Date
APRIL 24, 2013

NYS DOS ID#
4393276

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - GOOD HEALTH PHARMA & SUPPLIES INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Bio Roundup: Trumpcare is Mean, SCOTUS Says Go, Merck’s Myeloma No
    By Ben Fidler - Friday Jun 16, 2017

    What exactly does the American Health Care Act, the Republican proposal to replace Obamacare, currently look like? Few people know, because the Senate version is being negotiated behind closed doors in Washington D.C. without any public hearings. We do know President Trump now thinks the version of the AHCA that squeaked through the House is […]

    Source: Xconomy New York
  • Bio Roundup: Trumpcare is Mean, SCOTUS Says Go, Merck’s Myeloma No
    By Ben Fidler - Friday Jun 16, 2017

    What exactly does the American Health Care Act, the Republican proposal to replace Obamacare, currently look like? Few people know, because the Senate version is being negotiated behind closed doors in Washington D.C. without any public hearings. We do know President Trump now thinks the version of the AHCA that squeaked through the House is […]

    Source: Xconomy VC, Deals, & Startups Feed
  • Mylan Offered Discounts To States If They Made It Harder For Patients To Get Alternatives
    By Ashlee Kieler - Thursday Jun 22, 2017

    Controversial pharma company Mylan offered several states participating in Medicaid purchasing pools discounts on the EpiPen if they could ensure competitors’ products weren’t readily available to patients, according to a new report that raises additional concerns that the drugmaker engaged in anti-competitive practices as it raised the price of the life-saving drug nearly 400% in just 10 years. StatNews reports…

    Source: The Consumerist
  • Food & Wine Magazine Will Leave New York for Alabama
    By STEPHANIE STROM - Friday Jun 23, 2017

    The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.

    Source: NYT > Home Page
  • Pharma bro’s family may have tampered with witness
    By Emily Saul - Thursday Jun 22, 2017

    An unnamed member of “Pharma Bro” Martin Shkreli’s family may have engaged in witness tampering, authorities said Thursday. “A member of the defendant’s family has reached out to one of our witnesses, veering into the area of suggesting a witness not testify,” Assistant US Attorney Alixandria Eleis Smith responded after Shkreli’s lawyer, Marc Agnifilo, whined...

    Source: New York Post: Business
  • Charter promised more broadband but didn’t deliver, now must pay fine
    By Jon Brodkin - Thursday Jun 22, 2017

    21,000 NY customers did not get broadband on schedule, despite merger promise.

    Source: Ars Technica
  • Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More
    By Alex Lash - Friday Jun 9, 2017

    The New York Times Magazine wrote a few weeks ago about the extraordinary metabolic changes in a python after it gulps down a 50,000 calorie meal. The biomedical world was like a postprandial python this week; after extending its maw around the supersized meal of news and data from the American Society for Clinical Oncology […]

    Source: Xconomy New York
  • Attorneys trying to block media coverage of Pharma bro’s jury selection
    By Emily Saul - Thursday Jun 22, 2017

    Defense attorneys and prosecutors alike are attempting to bar media from certain aspects of Martin Shkreli’s jury selection — worried that press coverage of the notorious social media troll‘s jury selection could taint potential jurors. Both sides want to keep answers from potential jurors regarding Shkreli’s likability secret — as defense attorney Benjamin Braffman argued...

    Source: New York Post: Business